Endogenous, or therapeutically induced, type I interferon responses differentially modulate Th1/Th17-mediated autoimmunity in the CNS - PubMed (original) (raw)

Review

Endogenous, or therapeutically induced, type I interferon responses differentially modulate Th1/Th17-mediated autoimmunity in the CNS

Ulrich Kalinke et al. Immunol Cell Biol. 2012 May.

Free PMC article

Abstract

Different viruses trigger pattern recognition receptor systems, such as Toll-like receptors or cytosolic RIG-I like helicases (RLH), and thus induce early type I interferon (IFN-I) responses. Such responses may confer protection until adaptive immunity is activated to an extent that the pathogen can be eradicated. Interestingly, the same innate immune mechanisms that are relevant for early pathogen defense have a role in ameliorating experimental autoimmune encephalomyelitis (EAE), a rodent model of human multiple sclerosis. We and others found that mice devoid of a component of the IFN-I receptor (Ifnar1(-/-)) showed significantly enhanced autoimmune disease of the central nervous system (CNS). A detailed analysis revealed that in wild-type mice IFN-I triggering of myeloid cells was instrumental in reducing brain damage. A more recent study indicated that similar to Ifnar1(-/-) mice, RLH-signaling-deficient mice showed enhanced autoimmune disease of the CNS as well. Moreover, when peripherally treated with synthetic RLH ligands wild-type animals with EAE disease showed reduced clinical scores. Under such conditions, IFN-I receptor triggering of dendritic cells had a crucial role. The therapeutic effect of treatment with RLH ligands was associated with negative regulation of Th1 and Th17 T-cell responses within the CNS. These experiments are consistent with the hypothesis that spatiotemporal conditions of, and cell types involved in, disease-ameliorating IFN-I responses differ significantly, depending on whether they were endogenously induced in the context of EAE pathogenesis within the CNS or upon therapeutic RLH triggering in the periphery. It is attractive to speculate that RLH triggering represents a new strategy to treat multiple sclerosis by stimulating endogenous immunoregulatory IFN-I responses.

PubMed Disclaimer

Figures

Figure 1

Schematic depiction of the cellular mechanisms of endogenously induced versus therapeutically triggered type I interferon responses that modulate Th1/Th17-mediated autoimmunity in the CNS. (a) In EAE, IFN-I receptor engagement of myeloid cells (MQ) is critical to ameliorate disease burden. (b, c) Upon treatment with RLH ligands, therapeutic effects are (b) independent of IFN-I receptor triggering of myeloid cells (c) and dependent on IFN-I receptor triggering of DCs.

Cited by

Interferon β-Mediated Protective Functions of Microglia in Central Nervous System Autoimmunity.
Scheu S, Ali S, Mann-Nüttel R, Richter L, Arolt V, Dannlowski U, Kuhlmann T, Klotz L, Alferink J. Scheu S, et al. Int J Mol Sci. 2019 Jan 7;20(1):190. doi: 10.3390/ijms20010190. Int J Mol Sci. 2019. PMID: 30621022 Free PMC article. Review.
Interferon-β suppresses inflammatory pain through activating µ-opioid receptor.
Liu CC, Lu IC, Wang LK, Chen JY, Li YY, Yang CP, Liu PH, Cheng WJ, Tan PH. Liu CC, et al. Mol Pain. 2021 Jan-Dec;17:17448069211045211. doi: 10.1177/17448069211045211. Mol Pain. 2021. PMID: 34517736 Free PMC article.
Homeostatic interferon expression in neurons is sufficient for early control of viral infection.
Cavanaugh SE, Holmgren AM, Rall GF. Cavanaugh SE, et al. J Neuroimmunol. 2015 Feb 15;279:11-9. doi: 10.1016/j.jneuroim.2014.12.012. Epub 2014 Dec 16. J Neuroimmunol. 2015. PMID: 25669994 Free PMC article.
LRRC4 functions as a neuron-protective role in experimental autoimmune encephalomyelitis.
Zhang Y, Li D, Zeng Q, Feng J, Fu H, Luo Z, Xiao B, Yang H, Wu M. Zhang Y, et al. Mol Med. 2021 May 1;27(1):44. doi: 10.1186/s10020-021-00304-4. Mol Med. 2021. PMID: 33932995 Free PMC article.
IFN-β Deficiency Results in Fatal or Demyelinating Disease in C57BL/6 Mice Infected With Theiler's Murine Encephalomyelitis Viruses.
Bühler M, Runft S, Li D, Götting J, Detje CN, Nippold V, Stoff M, Beineke A, Schulz T, Kalinke U, Baumgärtner W, Gerhauser I. Bühler M, et al. Front Immunol. 2022 Feb 9;13:786940. doi: 10.3389/fimmu.2022.786940. eCollection 2022. Front Immunol. 2022. PMID: 35222374 Free PMC article.

References

1. Takeuchi O, Akira S. Innate immunity to virus infection. Immunol Rev. 2009;227:75–86. - PMC - PubMed
1. Honda K, Takaoka A, Taniguchi T. Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors. Immunity. 2006;25:349–360. - PubMed
1. Swiecki M, Colonna M. Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance. Immunol Rev. 2010;234:142–162. - PMC - PubMed
1. Luft T, Pang KC, Thomas E, Hertzog P, Hart DN, Trapani J, et al. Type I IFNs enhance the terminal differentiation of dendritic cells. J Immunol. 1998;161:1947–1953. - PubMed
1. Longhi MP, Trumpfheller C, Idoyaga J, Caskey M, Matos I, Kluger C, et al. Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J Exp Med. 2009;206:1589–1602. - PMC - PubMed

Endogenous, or therapeutically induced, type I interferon responses differentially modulate Th1/Th17-mediated autoimmunity in the CNS - PubMed (original) (raw)